# Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment

> **NCT02077868** · PHASE3 · UNKNOWN · sponsor: **Mologen AG** · enrollment: 540 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **OTHER:** Usual Maintenance
- **DRUG:** MGN1703 treatment

## Key facts

- **NCT ID:** NCT02077868
- **Lead sponsor:** Mologen AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-09
- **Primary completion:** 2019-02
- **Final completion:** 2020-05
- **Target enrollment:** 540 (ESTIMATED)
- **Last updated:** 2019-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02077868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02077868, "Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02077868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*